Intraperitoneal alpha therapy with 224Ra-labeled microparticles combined with chemotherapy in an ovarian cancer mouse model
A novel alpha-therapy consisting of 224Ra-labeled calcium carbonate microparticles (224Ra-CaCO3-MP) has been designed to treat micrometastatic peritoneal disease via intraperitoneal (IP) administration. This preclinical study aimed to evaluate its efficacy and tolerability when given as a single tre...
Main Authors: | Roxanne Wouters, Sara Westrøm, Yani Berckmans, Matteo Riva, Jolien Ceusters, Tina B. Bønsdorff, Ignace Vergote, An Coosemans |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2022-10-01
|
Series: | Frontiers in Medicine |
Subjects: | |
Online Access: | https://www.frontiersin.org/articles/10.3389/fmed.2022.995325/full |
Similar Items
-
Effect of Particle Carriers for Intraperitoneal Drug Delivery on the Course of Ovarian Cancer and Its Immune Microenvironment in a Mouse Model
by: Roxanne Wouters, et al.
Published: (2022-03-01) -
Dual targeting with 224Ra/212Pb-conjugates for targeted alpha therapy of disseminated cancers: A conceptual approach
by: Asta Juzeniene, et al.
Published: (2023-01-01) -
Radiation safety considerations for the use of radium-224-calciumcarbonate-microparticles in patients with peritoneal metastasis
by: Simen Rykkje Grønningsæter, et al.
Published: (2023-02-01) -
Preclinical studies performed in appropriate models could help identify optimal timing of combined chemotherapy and immunotherapy
by: Yani Berckmans, et al.
Published: (2023-09-01) -
The Curies’ element: state of the art and perspectives on the use of radium in nuclear medicine
by: Sara Franchi, et al.
Published: (2023-11-01)